Omapro Needs Companion Diagnostic, Advisory Committee Says
ChemGenex must determine which chronic myeloid leukemia patients have the T351I mutation and could benefit from the drug.
ChemGenex must determine which chronic myeloid leukemia patients have the T351I mutation and could benefit from the drug.